We believe psilocybin-assisted psychotherapy is the answer to alcoholism and other substance use disorders, with current studies demonstrating its efficacy and long-lasting positive effects.
- Generally well-tolerated
- Produces rapid and sustained clinical effects
- Increases alcohol abstinence and reduction in alcohol consumption and heavy drinking days
An initial pilot study on AUD conducted by Dr. Michael Bogenschutz at the University of New Mexico produced statistically significant results with promising effect sizes.
Published in JAMA Psychiatry in August 2022, a Phase 2a clinical trial led by B. More principal investigator, Dr. Michael Bogenschutz, reported an 83% average reduction in heavy drinking among those receiving psilocybin combined with psychotherapy. Additionally, the study showed that 8 months after their first dose, almost half (48 percent) of those who received psilocybin stopped drinking altogether compared with 24 percent of the placebo group.
B.More’s FDA approved, randomized, double blind, active placebo-controlled, multicenter, Phase 2b trial will assess the efficacy and safety of synthetic psilocybin (SYNP-101) in treating moderate to severe AUD. The trial plans to enroll a total of 210 participants who will receive psychotherapy and one administration of 30mg of SYNP-101 or an active placebo. The primary objective of the trial is to determine the efficacy of psilocybin in reducing alcohol consumption during 24-weeks following treatment.
Having invested millions of dollars and undertaken over 10 years of research, B.More is now positioned to commence a pivotal trial designed to secure FDA approval of prescription medicine status for the use of psilocybin to treat alcoholism. Obtaining adequate funding for this trial remains a critical priority for helping the millions of Americans who struggle with alcohol dependence. We welcome your support in making better treatment options a reality.